Taipei, Taiwan, 12 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for December 2025 of NT$2,442 million, representing an increase of 67% YoY, mainly driven by the consolidation of Alvogen US starting in December 2025. Lotus' 2025 full year revenue increased by 10% YoY to NT$20,501 million, which included a contribution from Alvogen US of US$39.5 million. On a like-for-like basis, adjusting for the new contribution from Alvogen US and the intercompany revenue elimination (revenue of Lotus Parent Company was impacted by elimination of sales from Taiwan to US), Lotus’ full-year 2025 revenue would have reached NT$19,513 million, or a 5% YoY increase.
With the integration of Alvogen US underway, Lotus is well positioned to capture synergies from the acquisition and enter a new phase of growth.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Taipei, Taiwan, 12 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for December 2025 of NT$2,442 million, representing an increase of 67% YoY, mainly driven by the consolidation of Alvogen US starting in December 2025. Lotus' 2025 full year revenue increased by 10% YoY to NT$20,501 million, which included a contribution from Alvogen US of US$39.5 million. On a like-for-like basis, adjusting for the new contribution from Alvogen US and the intercompany revenue elimination (revenue of Lotus Parent Company was impacted by elimination of sales from Taiwan to US), Lotus’ full-year 2025 revenue would have reached NT$19,513 million, or a 5% YoY increase.
With the integration of Alvogen US underway, Lotus is well positioned to capture synergies from the acquisition and enter a new phase of growth.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com